Becky McCall May 19, 2021 Combining an investigational agent, cagrilintide (Novo Nordisk), with semaglutide, a glucagon-like peptide-1 (GLP-1) agonist, leads to greater weight loss than semaglutide alone in people with a body mass index (BMI) over 27 kg/m2, and the combination was well-tolerated, shows a phase 1 study. The research was presented at the online ECO 2021 meeting by Lone...
Tag: <span>Semaglutide</span>
Post
Semaglutide found to reduce body weight regardless of patient characteristics
by European Association for the Study of Obesity New research presented at this year’s European Congress on Obesity (held online, 10-13 May) shows that treatment with the drug semaglutide reduces body weight in adults with overweight or obesity, regardless of their baseline characteristics. However, the study showed that female participants had slightly better results than males and also that...
Post
Semaglutide found to be effective against type 2 diabetes
Semaglutide is safe and effective for the treatment of type 2 diabetes, according to a review published online May 13 in Diabetes, Obesity and Metabolism. Panagiotis Andreadis, M.D., from the Aristotle University of Thessaloniki in Greece, and colleagues conducted a systematic literature review to identify randomized controlled trialscomparing semaglutide with placebo or other antidiabetic agents. The primary outcome was...
- 1
- 2